Published on 25 Apr 2022 on GuruFocus.com via Yahoo Finance
Nkarta Scores Huge Gain on Cancer Treatment Results
Bargain hunters may want to feast their eyes on a South San Francisco-based biotech focusing on cancer treatments.
Nkarta Inc. (NASDAQ:NKTX) is at least as good as Fate Therapeutics Inc. (NASDAQ:FATE) at a tenth of the price, according to an April 25 article appearing on the website of pharma consulting group Evaluate.
Oops, make that a sixth. Thats because Nkarta jumped nearly 140% Monday to about $19 after the company announced positive results from a phase 1 clinical trial for two experimental chimeric antigen receptor natural killer therapies. NK cells are critical members of the innate immunity lymphocytes and have a critical role in host defense against malignant cells. Adoptive cell therapy using CAR redirects the specificity of the immune cell against a target-specific antigen.